Clinical trials: Alzheimer Dementia
Alzheimer Disease
A Study of the Biodistribution and Safety of [18F]GTP1 in Healthy Japanese Participants
The purpose of this study is to evaluate the biodistribution, safety and tolerability of a single dose of [18F]GTP1 as a tau targeted radiopharmaceutical in healthy Japanese participants.
- Trial name
- NCT04394845
- Testing
- [18F]GTP1
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Parkinson Disease, Alzheimer Disease
Autoimmune Features of Neurodegenerative Disorders
This study is being conducted to better understand the role of inflammation in Parkinson's disease (PD) and Alzheimer's disease (AD).
- Conditions
- Parkinson Disease, Alzheimer Disease, Mild Cognitive Impairment
- Trial name
- NCT04239079
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Columbia University
Autistic Disorders Spectrum, Adhd
Studies of Brain and Body Interaction
The goal of this study is to characterize biophysiolgoical signals as a comprehensive profile of the nervous systems in order to understand interactions between the brain and body, while an individual performs naturalistic…
- Conditions
- Autistic Disorders Spectrum, Adhd, Asperger Syndrome, Alzheimer Disease
- Trial name
- NCT03672266
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Rutgers University
Alzheimer Disease
A Phase 2a Study to Investigate REM0046127 in Mild to Moderate Alzheimer's Disease
The purpose of this study is to measure effects on CSF biomarkers, EEG and safety with REM0046127 oral suspension compared with placebo in subjects with mild to moderate Alzheimer disease.
- Trial name
- NCT05478031
- Testing
- REM0046127 High Dose, REM0046127 Low Dose
- Where
- 3 sites in Netherlands, Spain
- Volunteers
- 14 people
- Sponsor
- reMYND
Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study
The purpose of this study will be to evaluate the safety and tolerability of lecanemab at sequentially ascending doses in subjects with mild to moderate Alzheimer's disease (AD).
- Trial name
- NCT01230853
- Testing
- Active Comparator: A, Active Comparator B
- Where
- 8 sites in United States
- Volunteers
- 80 people
- Sponsor
- Eisai Inc.
Alzheimer's Disease
Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl®)
Alzheimer's disease (AD) is characterized by progressive subcortical and cortical neuronal degeneration. AD patients differ in the time course of neuronal degeneration and accompanying cognitive decline.
- Trial name
- NCT00523666
- Testing
- Galantamine (Reminyl®)
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Ludwig-Maximilians - University of Munich
Mild Cognitive Impairment, Alzheimer Disease
A Feasiblity Study of Green Activity Program for People Living With Memory Challenges
The purpose of this study is to test the Green Activity Program that was designed with people living with memory challenges and their study partners to see if it can be done and if they enjoy the program.
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Subjective Cognitive Decline (SCD)
- Trial name
- GAP (NCT06403345)
- Testing
- Green Activity Program
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Indiana University
Mild Cognitive Impairment, Alzheimer Disease
Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers
This study aims to provide clinical validation of EyeQuant, a fully automated retinal image analysis system for computation of vascular biomarkers indicative of cognitive disorders, using retinal fundus photographs collected from…
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Vascular Dementia
- Trial name
- NCT04567745
- Testing
- Retinal fundus photography
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Mayo Clinic
Alzheimer's Disease, Huntington's Disease
A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers
This study will evaluate the potential for a drug-drug interaction of Dimebon with ketoconazole and omeprazole, potent inhibitors of the drug metabolizing enzymes CYP3A4 and CYP2C19, respectively.
- Trial name
- NCT00931073
- Testing
- Dimebon alone, Dimebon + Ketoconazole, Dimebon + Omeprazole
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Depression
Personalized Prevention of Depression in the Workplace (e-pD-Work)
The main goal is to design, develop and evaluate a personalized intervention to prevent depression in the workplace, based on Information and Communication Technologies (ICTs), predictive risk algorithms and decision support…
- Trial name
- e-pD-Work (NCT04858737)
- Testing
- e-predictD-Work intervention, Brief psychoeducational messages
- Where
- Spain
- Volunteers
- 1,054 people
- Sponsor
- The Mediterranean Institute for the Advance of Biotechnology and Health Research
Alzheimer's Disease
A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease
This study will investigate safety, tolerability and pharmacokinetics of ABT-126 in up to 20 male and female subjects, between 55 to 90 years of age with mild to moderate Alzheimer's disease on stable doses of…
- Trial name
- NCT01482845
- Testing
- ABT-126
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Abbott
Alzheimer Disease (AD), Mild Cognitive Impairment (MCI)
Improving Dementia Care in Primary Practice
This clinical trial will evaluate a multi-level scalable intervention called Improving Dementia Care (IDC). The investigators hypothesize that IDC will increase dementia detection in patients with impaired cognition more than the…
- Conditions
- Alzheimer Disease (AD), Mild Cognitive Impairment (MCI), Dementia
- Trial name
- IDC (NCT07526480)
- Testing
- Improving Dementia Care, Enhanced Usual Care
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Alzheimer Disease
Identification of Proteostasis-related Biomarkers in Alzheimer´s Dementia
At the time of biomarker-substantiated diagnosis for a given AD patient it remains unclear to what extent the disease will devastate cognitive abilities within the next years.
- Trial name
- NCT02686554
- Testing
- Neuropsychological assessment
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Charite University, Berlin, Germany
Mild Cognitive Impairment, Alzheimer Disease
Causal Effect of Coenzyme Q10 Nutrition and Cognitive Dysfunction in the Metabolic Storm (Hyperglycemia and Sarcopenia) and Brain-derived Neurotrophic Factor
The aim of the study is to investigate the effects of coenzyme Q10 supplementation (150 mg twice daily; 300 mg/day for 12 weeks) on coenzyme Q10 status, glucose parameters, BDNF, myokines, and cognitive function in patients with…
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Hyperglycemia, Pre-sarcopenia
- Trial name
- NCT06040905
- Testing
- Coenzyme Q10
- Where
- Taiwan
- Volunteers
- 51 people
- Sponsor
- Chung Shan Medical University
Alzheimer's Disease
Phase II Study of Intravenous Immunoglobulin (IVIg) for Alzheimer's Disease
The overall goal of this double-blind Phase II study is to evaluate the safety, efficacy and biological mechanisms of action of Intravenous Immunoglobulin (IVIg) in the treatment of mild to moderate stage Alzheimer's disease…
- Trial name
- NCT00299988
- Testing
- Intravenous Immunoglobulin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Weill Medical College of Cornell University
Multiple Myeloma
Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects
The purpose of this study is to see if MRI techniques can be used for early evaluation of cardiac amyloidosis which is sometimes seen in individuals with multiple myeloma.
- Trial name
- NCT01018927
- Testing
- Administering three additional MRI images
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Arkansas
Dementia, Alzheimer Disease
Partners in Dementia Care: A Telephone Care Consultation Intervention Provided to Veterans in Partnership With Local Alzheimer's Association Chapters
Background: Partners in Dementia Care (PDC) is a care coordination and support service intervention for veterans with dementia and their family caregivers, delivered through partnerships between VA medical centers and local…
- Trial name
- PDC (NCT00291161)
- Testing
- Partners in Dementia Care
- Where
- 6 sites in United States
- Volunteers
- 994 people
- Sponsor
- VA Office of Research and Development
Alzheimer's Disease
Tau Imaging in Professional Fighters
Subjects enrolled in the Professional Fighters Brain Health Study (PFBHS) will receive flortaucipir to explore its use as a biomarker for brain injury related to repetitive head trauma and to examine the relationship between…
- Trial name
- NCT02278354
- Testing
- Flortaucipir F18, Brain PET scan
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer Disease
Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
This is a phase 2b, double-blind, placebo controlled proof-of-concept study of a an oral small molecule selective inhibitor of p38 alpha kinase, neflamapimod, administered for 24 weeks in subjects with mild Alzheimer's disease.
- Trial name
- REVERSE-SD (NCT03402659)
- Testing
- neflamapimod
- Where
- 38 sites in United States, Czechia and 3 more
- Volunteers
- 161 people
- Sponsor
- EIP Pharma Inc
Alzheimer's Disease
Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease
The purpose of this study is to determine whether single doses of PF-04360365 is safe and well tolerated in patients with Alzheimer's Disease.
- Trial name
- NCT00733642
- Testing
- PF-04360365 1 mg/kg, PF-04360365 3 mg/kg, PF-04360365 5 mg/kg
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.